Journal
NEUROLOGY
Volume 72, Issue 11, Pages 1008-1015Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000344417.42972.54
Keywords
-
Categories
Funding
- Bayer
- Biogen Idec/Elan
- Sanofi-Aventis
- Schering
- Serono
- Teva Pharmaceuticals
Ask authors/readers for more resources
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions. Neurology (R) 2009; 72: 1008-1015
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
